Tivorbex is a new formulation of indomethacin, a drug prescribed for arthritis, gout, and other pain.
It uses Iroko's 'fine particle technology,' which delivers higher pain relief at a 20% lower dose than conventional NSAIDs.
That is designed to reduce the side effects of NSAIDs, especially stomach bleeding.
Tivorbex was approved by the FDA in 20 mg and 40 mg doses for mild to moderate acute pain in adults.
Iroko's other drug, Zorvolex, officially went on the market in January.
There's been no sales date specified for Tivorbex.
